Alnylam Pharmaceuticals (ALNY) Stock Analysis & Winston Score

Alnylam Pharmaceuticals is a biotech company that makes medicines using a technology called RNA interference, or RNAi. This technology works by silencing specific genes in the body that cause disease. Alnylam focuses on rare and serious conditions, including a nerve disease called hereditary transthyretin amyloidosis (hATTR) and high triglycerides, selling drugs like Onpattro, Amvuttra, and Leqvio to patients and healthcare systems worldwide. The company earns money primarily through drug sales and also through royalties and partnerships with larger pharmaceutical companies like Novartis. Alnylam operates mainly in the US and Europe, with a growing global footprint, and its core competitive advantage is its pioneering position in RNAi — a platform that took decades and billions of dollars to develop, making it hard for rivals to replicate quickly. The key growth driver is expanding its approved drug portfolio and pipeline into more common diseases like cardiovascular conditions, though the main risk is the high cost of developing new drugs and potential competition from other gene-silencing technologies.